Check for updates

#### **OPEN ACCESS**

EDITED BY Giuseppe Quero, Agostino Gemelli University Polyclinic (IRCCS), Italy

REVIEWED BY Akira Umemura, Iwate Medical University, Japan Audrius Dulskas, National Cancer Institute, Lithuania

\*CORRESPONDENCE Wenjiang Wu ⊠ 1053660645@qq.com

RECEIVED 02 February 2023 ACCEPTED 21 April 2023 PUBLISHED 12 May 2023

#### CITATION

Xia S, Wu W, Luo L, Ma L, Yu L and Li Y (2023) Indocyanine green fluorescence angiography decreases the risk of anastomotic leakage after rectal cancer surgery: a systematic review and meta-analysis. *Front. Med.* 10:1157389. doi: 10.3389/fmed.2023.1157389

#### COPYRIGHT

© 2023 Xia, Wu, Luo, Ma, Yu and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Indocyanine green fluorescence angiography decreases the risk of anastomotic leakage after rectal cancer surgery: a systematic review and meta-analysis

Shijun Xia<sup>1</sup>, Wenjiang Wu<sup>1\*</sup>, Lidan Luo<sup>1</sup>, Lijuan Ma<sup>2</sup>, Linchong Yu<sup>1</sup> and Yue Li<sup>1</sup>

<sup>1</sup>Shenzhen Hospital of Guangzhou University of Chinese Medicine, Shenzhen, China, <sup>2</sup>Shenzhen Traditional Chinese Medicine Anorectal Hospital, Shenzhen, China

**Background:** Anastomotic leakage is a serious complication after rectal cancer resection. Intraoperative use of indocyanine green fluorescence angiography (ICGFA) can help prevent anastomotic leakage, but its use is controversial. We conducted a systematic review and meta-analysis to determine the efficacy of ICGFA in reducing anastomotic leakage.

**Methods:** Relevant data and research published until September 30, 2022, was retrieved from the PubMed, Embase, and Cochrane Library databases, and the difference in the incidence of anastomotic leakage after rectal cancer resection between ICGFA and standard treatment was compared.

**Results:** This meta-analysis included 22 studies with a total of 4,738 patients. The results showed that ICGFA use during surgery decreased the incidence of anastomotic leakage after rectal cancer surgery [risk ratio (RR) = 0.46; 95% confidence interval (95% CI), 0.39–0.56; p < 0.001]. Simultaneously, in subgroup analyses for different regions, ICGFA was found to be used to reduce the incidence of anastomotic leakage after rectal cancer surgery in Asia (RR = 0.33; 95% CI, 0.23–0.48; p < 0.0001) and Europe (RR = 0.38; 95% CI, 0.27–0.53; p < 0.00001) but not in North America (RR = 0.72; 95% CI, 0.40–1.29; p = 0.27). Regarding different levels of anastomotic leakage, ICGFA reduced the incidence of postoperative type A anastomotic leakage (RR = 0.25; 95% CI, 0.14–0.44; p < 0.00001) but did not reduce the incidence of type B (RR = 0.70; 95% CI, 0.38–1.31; p = 0.27) and type C (RR = 0.97; 95% CI, 0.51–1.97; p = 0.93) anastomotic leakages.

**Conclusion:** ICGFA has been linked to a reduction in anastomotic leakage after rectal cancer resection. However, multicenter randomized controlled trials with larger sample sizes are required for further validation.

#### KEYWORDS

anastomotic leakage, fluorescence angiography, indocyanine green, meta-analysis, rectal cancer

# Introduction

Rectal cancer morbidity and mortality are increasing (1). With the advancement in pathophysiology, current individualized treatments for rectal cancer include endoscopic, local surgical resection, systemic treatment, preoperative radiotherapy, local ablation treatment for metastatic tumors, extensive surgery for local and metastatic diseases, targeted

therapy, palliative chemotherapy, and immunotherapy, whereas surgery is the cornerstone of curative intent treatment (1). However, rectal cancer patients may face many complications after resection, one of which is anastomotic leakage.

Despite significant advances in surgical techniques and perioperative management in recent years, the incidence of anastomotic leakage after rectal cancer surgery remains between 5 and 19% (2). The occurrence of anastomotic leakage will result in prolonged hospitalization, increased hospitalization costs, increased local recurrence rate, and shortened survival time (3– 5). Studies have shown that the risk factors for anastomotic leakage have been determined by age, male gender, smoking, diabetes, previous radiotherapy and chemotherapy, intraoperative complications, anastomotic tension, and low perfusion (2, 6, 7). Among these, insufficient blood perfusion at the anastomosis plays an important role in the pathogenesis of anastomotic leakage (7).

Indocyanine green fluorescent angiography (ICGFA) is widely used in many surgical fields (8-10), including gastrointestinal surgery. The ICGFA allows the surgeon to visualize the blood supply of the intestinal canal and avoid inadequate perfusion of the anastomosis during colorectal surgery. The doctor injected diluted indocyanine green (ICG) into the venous system and monitored the development signal with a fluorescent laparoscope. When the ICG enters the anastomosis area to be observed, the doctor can dynamically observe the blood supply of the colorectal anastomosis with the fluorescent display. Therefore, intraoperative ICG use for intestinal anastomosis blood supply imaging could theoretically become a predictive test to evaluate anastomotic perfusion, reducing the risk of anastomotic leakage. Some metaanalyses have recently revealed that ICGFA can help reduce the incidence of anastomotic leakage after rectal cancer surgery (11-13). However, most of them are not convincing due to the limited number of good qualities RCT studies included and the small number of patients.

According to recently published research, we updated this meta-analysis to evaluate whether this technique can reduce the anastomotic leakage rate of rectal cancer patients after resection.

# Materials and methods

This systematic review and meta-analysis is based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statements (PRISMA) (14). Because this study is a metaanalysis, neither institutional review committee approval nor patient-informed consent was required.

## Study strategy

We conducted a comprehensive and systematic search of electronic databases, including PubMed, Embase, and the Cochrane Library; retrieved relevant research published until September 30, 2022; and identified potential articles using the following keyword combinations: ("indocyanine green" OR "fluorescein angiography" OR "fluorescence imaging" OR "indocyanine green-sulfo-OSu" OR "ICG") AND ("Rectal Neoplasm" OR "Rectal Tumor" OR "Rectal Cancer" OR "Rectum Cancer"). Simultaneously, we searched the



reference list and previous comments in these studies for more comprehensive studies that could be included. Two authors (SJ-X and WJ-W) worked independently on this study.

## Anastomotic leakage definition

Anastomotic leakage was defined as a defect in the anastomotic region where there is communication between the intraluminal and extraluminal chambers. Anastomotic leakage was graded by the International Research Group on Rectal Cancer based on its clinical symptoms. Type A had the mildest clinical symptoms, and type C had the most severe clinical symptoms (15). Type A anastomotic leakage is referred to as subclinical leakage or imaging leakage, whereas type B and C anastomotic leakages are referred to as clinical leakage or significant leakage.

# Inclusion and exclusion criteria

The inclusion criteria of this study were as follows: (a) patients undergoing rectal cancer surgery; (b) the report result compares the incidence of anastomotic leakage between the ICGFA group

#### TABLE 1 Characteristics of the included trials.

References	Country	Study design			ICG gro	oup				Non-ICG g	jroup		NOS
			No.	AL no.	AL grade A no.	AL grade B no.	AL grade C no.	No.	AL no.	AL grade A no.	AL grade B no.	AL grade C no.	
Jafari et al. (16)	USA	Retrospective	16	1				22	4				6
Kim et al. (17)	Korea	Retrospective	310	2				347	18				8
Boni et al. (18)	Italy	Retrospective	42	0				38	2				7
Brescia et al. (19)	Italy	Retrospective	21	0				31	4				5
Mizrahi et al. (20)	USA	Retrospective	30	0				30	2				8
Ris et al. (21)	Switzerland	Prospectively	90	3				365	39				6
Shapera et al. (22)	USA	Prospectively	58	0				23	1				6
Watanabe et al. (23)	Japan	Retrospective	211	10				211	22				8
De Nardi et al. (24)	Italy	RCT	56	4				53	7				9
Wada et al. (25)	Japan	Retrospective	48	5	0	1	4	101	7	0	4	3	7
Zhou et al. (26)	China	Retrospective	12	1				30	0				6
Alekseev et al. (27)	Russia	RCT	111	16	7	6	3	104	27	19	7	1	9
Bonadio et al. (28)	Italy	Retrospective	33	2	1	1	0	33	7	3	1	3	7
Foo et al. (29)	China	Retrospective	253	9	2	3	4	253	20	5	10	5	6
Hasegawa et al. (30)	Japan	Retrospective	141	4				403	87				8
Impellizzeri et al. (31)	Italy	Retrospective	37	0				36	2				5
Skrovina et al. (32)	Czech Republic	Retrospective	50	5	2	2	1	20	9	8	1	0	6
Wojcik et al. (33)	France	Prospectively	26	1				42	6				7
Ishii et al. (34)	Japan	Retrospective	116	4				104	11				8
Benčurik et al. (35)	Czech Republic	Retrospective	100	9	2	4	3	100	19	13	1	5	7
Jafari et al. (36)	USA	RCT	178	16				169	16				9
Otero Piñeiro et al. (37)	Spain	Retrospective	80	2				204	23				5

ICG, Indocyanine green; AL, anastomotic leakage; NOS, Newcastle Ottawa Scale.



and the control group; and (c) the study design was a randomized controlled trial (RCT), prospective trial, or retrospective trial.

The exclusion criteria were as follows: (a) the study was published in the form of comments, case reports, and letters; (b) the data were insufficient or could not be obtained from the author for meta-analysis; and (c) all inconsistent articles that were ruled by the third examiner (Y-L).

# Data extraction

The two authors (SJ-X and LD-L) conducted independent research and were selected to extract data at the same time based on the inclusion and exclusion criteria. Each included article provided the following information: first author, publication year, research country, research design, and the number of anastomotic leakages.

## Quality assessment

After reading the full text of each included study, the two authors (LJ-M and LC-Y) independently evaluated the quality of the study using the Newcastle Ottawa Scale (NOS). The NOS includes the following four areas: patient selection quality, exposure determination, group comparability, and patient results. The total NOS score ranges from 0 to 9, with a score  $\geq 6$  indicating high quality.

## Outcomes

The purpose of this study was to compare the incidence of anastomotic leakages in patients undergoing rectal cancer surgery with and without ICG. The secondary analysis was a subgroup analysis, which included the difference in the incidence of anastomotic leakages between regions and grades.

# Statistical analysis

This study is primarily based on binary data. The risk ratio (RR) is used as the effect measure, with a 95% confidence interval. All statistical tests had a significance level of p < 0.05 (double-tailed).  $I^2$  statistics was used to determine heterogeneity, with results ranging from 0 to 100%. When  $I^2 = 0$ %, heterogeneity was assumed as not observed;  $I^2 = 25$ %, heterogeneity was low;  $I^2 = 50$ %, heterogeneity was medium; and  $I^2 = 75$ %, heterogeneity was high. When  $I^2 < 50$ %, a fixed model effect was used. The random model effect was used for all other cases. This study was conducted using the Review Manager software version 5.3 (Nordic Cochrane Center, Cochrane Collaboration, London, UK).

Study or Subgroup         Fevents         Total         Weight         M-H, Fixed, 95% CI         Meta Nation           1.3.1 Grade A         Velocity         101         19         104         37.7%         0.35 [0.15, 0.79]         Meta H, Fixed, 95% CI         M-H, Fixed, 95% CI           Senčurik 2021         2         100         13         100         25.0%         0.15 [0.04, 0.66]         Senčurik 2021         2         100         13         100         25.0%         0.33 [0.04, 3.04]         Senčurik 2021         2         50         8         20         22.0%         0.10 [0.02, 0.43]         Senčurik 2021         100         48         0         101         Not estimable         Senčurik 2021         104         48         101         Not estimable         Senčurik 2021         104         11         100.0%         0.25 [0.14, 0.44]         Foreitrable         Senčurik 2021         101         100         4.3%         4.00 [0.48, 35.16]         Senčurik 2021         103         103         4.3%         4.00 [0.48, 35.16]         Senčurik 2021         102         Senčurik 203         Senčurik 2021         102         Senčurik 203         Senčurik 2021         102         Senčurik 203         Senčurik 204         Senčurik 204         Senčurik 204         Senčurik 204 <td< th=""></td<>
$\begin{array}{c c c c c c c c c c c c c c c c c c c $
New Series 2020 7 111 19 104 37.7% 0.35 [0.15, 0.79] Benčurik 2021 2 100 13 100 25.0% 0.15 [0.04, 0.66] Sonadio 2020 1 33 3 35 6.8% 0.33 [0.04, 3.04] Sonadio 2020 2 253 5 253 9.6% 0.40 [0.08, 2.04] Skrovina 2020 2 50 8 20 22.0% 0.10 [0.02, 0.43] Not estimable Subtotal (95% CI) 595 611 100.0% 0.25 [0.14, 0.44] Total events 14 48 Heterogeneity: $Chi^{2} = 2.91$ , $df = 4$ ( $P = 0.57$ ); $P = 0%$ Fest for overall effect $Z = 4.83$ ( $P < 0.00001$ ) L3.2 Grade B Nekseev 2020 6 111 7 104 31.1% 0.80 [0.28, 2.31] Sonadio 2020 1 33 1 33 4.3% 1.00 [0.07, 15.33] Sonadio 2020 2 50 1 20 6.1% 0.80 [0.08, 8.108] Skrovina 2020 2 50 1 20 6.1% 0.80 [0.08, 8.108] Skrovina 2020 2 50 5 611 100.0% 0.70 [0.38, 1.31] Total events 17 24 Heterogeneity: $Chi^{2} = 4.37$ , $df = 5$ ( $P = 0.50$ ); $P = 0%$ Fest for overall effect $Z = 1.11$ ( $P = 0.27$ ) L3.3 Grade C Nekseev 2020 3 111 1 104 6.0% 2.81 [0.30, 26.60] Senčurik 2021 3 100 5 100 29.1% 0.60 [0.15, 2.44] Sonadio 2020 0 33 3 33 20.4% 0.14 [0.01, 2.294]
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
$\begin{array}{cccccccccccccccccccccccccccccccccccc$
$\begin{array}{c} \text{Stricture 2020} & 1 & 253 & 5 & 253 & 9.0\% & 0.408 [0.08, 2.04] \\ \text{Skrovina 2020} & 2 & 50 & 8 & 20 & 22.0\% & 0.10 [0.02, 0.43] \\ \text{Nada 2019} & 0 & 48 & 0 & 101 & \text{Not estimable} \\ \text{Subtotal (95% CI)} & 595 & 611 & 100.0\% & 0.25 [0.14, 0.44] \\ \text{Feterogeneity: Chi2 = 2.91, df = 4 (P = 0.57); P = 0\% \\ \text{Fest for overall effect: } Z = 4.83 (P < 0.00001) \\ \textbf{I.3.2 Grade B} \\ \text{Nekseev 2020} & 6 & 111 & 7 & 104 & 31.1\% & 0.80 [0.28, 2.31] \\ \text{3onadio 2020} & 1 & 33 & 1 & 33 & 4.3\% & 1.00 [0.08, 1.08] \\ \text{Skrovina 2020} & 2 & 50 & 1 & 20 & 6.1\% & 0.80 [0.08, 8.34] \\ \text{Nada 2019} & 1 & 48 & 4 & 101 & 11.1\% & 0.53 [0.06, 4.58] \\ \text{Skrovina 2020} & 2 & 50 & 1 & 20 & 6.1\% & 0.80 [0.08, 8.34] \\ \text{Nada 2019} & 1 & 48 & 4 & 101 & 11.1\% & 0.53 [0.06, 4.58] \\ \text{Subtotal (95% CI)} & 595 & 611 & 100.0\% & 0.70 [0.38, 1.31] \\ \text{Total events} & 17 & 24 \\ \text{teterogeneity: Chi2 = 4.37, df = 5 (P = 0.50); P = 0\% \\ \text{Fest for overall effect: } Z = 1.11 (P = 0.27) \\ \textbf{I.3.3 Grade C} \\ \text{Nekseev 2020} & 3 & 111 & 1 & 104 & 6.0\% & 2.81 [0.30, 26.60] \\ \text{Senčurik 2021} & 3 & 100 & 5 & 100 & 29.1\% & 0.60 [0.15, 2.44] \\ \text{Sonadio 2020} & 0 & 33 & 3 & 33 & 2.04\% & 0.14 [0.01, 2.66] \\ \text{Senčurik 2021} & 3 & 100 & 5 & 100 & 29.1\% & 0.60 [0.12, 2.94] \\ \text{Sonadio 2020} & 0 & 33 & 3 & 33 & 2.94\% & 0.14 [0.01, 2.66] \\ \text{Sonadio 2020} & 0 & 33 & 3 & 33 & 2.94\% & 0.14 [0.01, 2.26] \\ \text{Sonadio 2020} & 0 & 33 & 3 & 33 & 2.94\% & 0.14 [0.01, 2.26] \\ \text{Sonadio 2020} & 0 & 33 & 3 & 33 & 2.94\% & 0.14 [0.01, 2.26] \\ \text{Sonadio 2020} & 0 & 33 & 3 & 33 & 32 & 2.94\% & 0.14 [0.01, 2.26] \\ \text{Sonadio 2020} & 0 & 33 & 3 & 33 & 2.94\% & 0.14 [0.01, 2.26] \\ \text{Sonadio 2020} & 0 & 33 & 3 & 33 & 2.94\% & 0.14 [0.01, 2.26] \\ \text{Sonadio 2020} & 0 & 33 & 3 & 33 & 2.94\% & 0.14 [0.01, 2.26] \\ \text{Sonadio 2020} & 0 & 33 & 3 & 33 & 2.94\% & 0.14 [0.01, 2.26] \\ \text{Sonadio 2020} & 0 & 33 & 3 & 33 & 2.94\% & 0.14 [0.01, 2.26] \\ \text{Sonadio 2020} & 0 & 33 & 3 & 33 & 2.94\% & 0.14 [0.01, 2.26] \\ \text{Sonadio 2020} & 0 & 33 & 3 & 33 & 32 & 2.94\% & 0.80 & 10.22 & 2.94 \\ Sonadio$
Solo 2020       1       203       35       103       0.45       0.45       0.45       0.45         Skrovina 2020       2       50       8       20       22.0%       0.10       [0.02, 0.43]         Wada 2019       0       48       0       101       Not estimable         Subtotal (95% CI)       595       611       100.0%       0.25 [0.14, 0.44]         Fost for overall effect: Z = 4.83 (P < 0.00001)
Alignment 1010       1
Nature 2013       0       101       100.0%       0.25 [0.14, 0.44]         Total events       14       48         Heterogeneity: Chi <sup>2</sup> = 2.91, df = 4 (P = 0.57); P = 0%         Test for overall effect: Z = 4.83 (P < 0.00001)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$
$\begin{array}{c} \text{Intervents} & \text{Int} $
Trest for overall effect: $Z = 4.83$ (P < 0.00001) <b>1.3.2 Grade B</b> Nekseev 2020 6 111 7 104 31.1% 0.80 [0.28, 2.31] 3enčurik 2021 4 100 1 100 4.3% 4.00 [0.46, 35.16] 3onadio 2020 1 33 1 33 4.3% 1.00 [0.07, 15.33] 5oo 2020 3 253 10 253 43.0% 0.30 [0.08, 1.08] Skrovina 2020 2 50 1 20 6.1% 0.80 [0.08, 8.34] Vada 2019 1 48 4 101 11.1% 0.53 [0.06, 4.58] Subtotal (95% CI) 595 611 100.0% 0.70 [0.38, 1.31] Total events 17 24 Heterogeneity: Chi <sup>2</sup> = 4.37, df = 5 (P = 0.50); I <sup>2</sup> = 0% Fest for overall effect: $Z = 1.11$ (P = 0.27) <b>1.3.3 Grade C</b> Nekseev 2020 3 111 1 100 29.1% 0.60 [0.15, 2.44] 3onadio 2020 0 33 3 33 20.4% 0.14 [0.01, 2.66] = 0.2020 4 253 5 253 291% 0.80 [0.22 2.94]
<b>1.3.2 Grade B</b> Alekseev 2020       6       111       7       104       31.1%       0.80 [0.28, 2.31]         Benčurik 2021       4       100       1       100       4.3%       4.00 [0.46, 35.16]         Bonadio 2020       1       33       1       33       4.3%       1.00 [0.07, 15.33]         Foo 2020       3       253       10       253       43.0%       0.30 [0.08, 1.08]         Skrovina 2020       2       50       1       20       6.1%       0.80 [0.08, 8.34]         Wada 2019       1       48       4       101       11.1%       0.53 [0.06, 4.58]         Subtotal (95% CI)       595       611       100.0%       0.70 [0.38, 1.31]         Total events       17       24         4eterogeneity: Chi <sup>2</sup> = 4.37, df = 5 (P = 0.50); I <sup>2</sup> = 0%       Fest for overall effect: Z = 1.11 (P = 0.27)         I.3.3 Grade C       Image: Stroke C       Image: Stroke C       Image: Stroke C         Vekseev 2020       3       111       1       104       6.0%       2.81 [0.30, 26.60]         Benčurik 2021       3       100       5       100       29.1%       0.60 [0.15, 2.44]         Bonadio 2020       0       33       33 </td
1.3.2 Grade B         Alekseev 2020       6       111       7       104       31.1%       0.80 [0.28, 2.31]         Benčurik 2021       4       100       1       100       4.3%       4.00 [0.46, 35.16]         Bonadio 2020       1       33       1       33       4.3%       1.00 [0.07, 15.33]         Foo 2020       3       253       10       253       43.0%       0.30 [0.08, 1.08]         Skrovina 2020       2       50       1       20       6.1%       0.80 [0.08, 8.34]         Wada 2019       1       48       4       101       11.1%       0.53 [0.06, 4.58]         Subtotal (95% CI)       595       611       100.0%       0.70 [0.38, 1.31]         Fotal events       17       24         Heterogeneity: Chi <sup>2</sup> = 4.37, df = 5 (P = 0.50); i <sup>2</sup> = 0%       Fest for overall effect: Z = 1.11 (P = 0.27)         I.3.3 Grade C       Image: State of the s
Alekseev 2020       6       111       7       104 $31.1\%$ 0.80 [0.28, 2.31]         Benčurik 2021       4       100       1       100 $4.3\%$ 4.00 [0.46, 35.16]         Bonadio 2020       1       33       1       33       4.3%       1.00 [0.07, 15.33]         Foo 2020       3       253       10       253       43.0%       0.30 [0.08, 1.08]         Skrovina 2020       2       50       1       20       6.1%       0.80 [0.08, 1.08]         Skrovina 2020       2       50       1       20       6.1%       0.80 [0.08, 1.08]         Skrovina 2020       2       50       1       20       6.1%       0.80 [0.08, 8.34]         Vada 2019       1       48       4       101       11.1%       0.53 [0.06, 4.58]         Subtotal (95% CI)       595       611       100.0%       0.70 [0.38, 1.31] $\bullet$ Total events       17       24 $\bullet$ $\bullet$ $\bullet$ $\bullet$ $\bullet$ I.3.3 Grade C
Bandwirk 2021       4       100       1       100       4.3%       4.00 [0.46, 35.16]         Bondalo 2020       1       33       1       33       4.3%       1.00 [0.07, 15.33]         Foo 2020       3       253       10       253       43.0%       0.30 [0.08, 1.08]         Skrovina 2020       2       50       1       20       6.1%       0.80 [0.08, 1.08]         Skrovina 2020       2       50       1       20       6.1%       0.80 [0.08, 1.08]         Skrovina 2020       2       50       1       20       6.1%       0.80 [0.08, 1.08]         Skrovina 2020       2       50       1       20       6.1%       0.80 [0.08, 8.34]         Wada 2019       1       48       4       101       11.1%       0.53 [0.06, 4.58]         Subtotal (95% CI)       595       611       100.0%       0.70 [0.38, 1.31]       100         Fest for overall effect: $Z = 1.11$ ( $P = 0.27$ )       1.3       6.0%       2.81 [0.30, 26.60]       1.41       1.41         Benčurik 2021       3       100       5       100       29.1%       0.60 [0.15, 2.44]       1.41       1.41         Bonadio 2020       0       33       3
Bonadio 2020       1       33       1       33       4.3%       1.00 [0.07, 15.33]         Foo 2020       3       253       10       253       43.0%       0.30 [0.08, 1.08]         Skrovina 2020       2       50       1       20       6.1%       0.80 [0.08, 8.34]         Wada 2019       1       48       4       101       11.1%       0.53 [0.06, 4.58]         Subtotal (95% CI)       595       611       100.0%       0.70 [0.38, 1.31]         Fotal events       17       24         Heterogeneity: Chi <sup>2</sup> = 4.37, df = 5 (P = 0.50); l <sup>2</sup> = 0%       Fest for overall effect: $Z = 1.11$ (P = 0.27)         I.3.3 Grade C       Image: Strong the s
Solution 2020       3       253       10       253       43.0%       0.30 [0.08, 1.08]         Skrovina 2020       2       50       1       20       6.1%       0.80 [0.08, 8.34]         Wada 2019       1       48       4       101       11.1%       0.53 [0.06, 4.58]         Subtotal (95% CI)       595       611       100.0%       0.70 [0.38, 1.31]         Fotal events       17       24         Heterogeneity: Chi² = 4.37, df = 5 (P = 0.50); l² = 0%         Fest for overall effect: Z = 1.11 (P = 0.27)         I.3.3 Grade C         Nekseev 2020       3       111       1       104       6.0%       2.81 [0.30, 26.60]         Senčurik 2021       3       100       5       100       29.1%       0.60 [0.15, 2.44]         Sonadio 2020       0       33       3       32       2.94 %       0.80 [0.22, 2.94]
Skrovina 2020       2       50       10       100       400 4       610 (0.08, 8.34)         Wada 2019       1       48       4       101       11.1%       0.53 (0.06, 4.58)         Subtotal (95% CI)       595       611       100.0%       0.70 [0.38, 1.31]         Fotal events       17       24         Heterogeneity: Chi² = 4.37, df = 5 (P = 0.50); l² = 0%       Fest for overall effect: Z = 1.11 (P = 0.27)         I.3.3 Grade C
Avada 2019       1       48       4       101       11.1%       0.53 [0.06, 4.58]         Subtotal (95% CI)       595       611       100.0%       0.70 [0.38, 1.31]         Fotal events       17       24         Heterogeneity: Chi² = 4.37, df = 5 (P = 0.50); l² = 0%         Fest for overall effect: Z = 1.11 (P = 0.27)         I.3.3 Grade C         Nekseev 2020       3         3       100       5       100       29.1%       0.60 [0.15, 2.44]         3onadio 2020       0       33       3       32 0.4%       0.14 [0.01, 2.66]         ion 2020       4       253       5       253       29 1%       0.80 [0.22, 2.94]
Subtotal (95% CI)       595       611       100.0%       0.70 [0.38, 1.31]         Total events       17       24         Heterogeneity: Chi² = 4.37, df = 5 (P = 0.50); l² = 0%         Fest for overall effect: Z = 1.11 (P = 0.27)         I.3.3 Grade C         Alekseev 2020       3       111       1       104       6.0%       2.81 [0.30, 26.60]         Senčurik 2021       3       100       5       100       29.1%       0.60 [0.15, 2.44]         Sonadio 2020       0       33       3       32       20.4%       0.14 [0.01, 2.66]
Total events 17 24 Heterogeneity: Chi <sup>2</sup> = 4.37, df = 5 (P = 0.50); l <sup>2</sup> = 0% Fest for overall effect: Z = 1.11 (P = 0.27) <b>1.3.3 Grade C</b> Alekseev 2020 3 111 1 104 6.0% 2.81 [0.30, 26.60] 3enčurik 2021 3 100 5 100 29.1% 0.60 [0.15, 2.44] 3onadio 2020 0 33 3 33 20.4% 0.14 [0.01, 2.66] 5on 2020 4 253 5 253 29 1% 0.80 [0.22, 2.94]
Heterogeneity: Chi <sup>2</sup> = 4.37, df = 5 (P = 0.50); l <sup>2</sup> = 0% Fest for overall effect: Z = 1.11 (P = 0.27) <b>1.3.3 Grade C</b> Alekseev 2020 3 111 1 104 6.0% 2.81 [0.30, 26.60] 3enčurik 2021 3 100 5 100 29.1% 0.60 [0.15, 2.44] 3onadio 2020 0 33 3 33 20.4% 0.14 [0.01, 2.66] 5 0 2020 4 253 5 253 29 1% 0.80 [0.22, 2.94]
Test for overall effect: Z = 1.11 (P = 0.27)         I.3.3 Grade C         Nekseev 2020       3 111         3 100       5 100         29.1%       0.60 [0.15, 2.44]         3onadio 2020       0 33         3 3       20.4%         0.14 [0.01, 2.66]
I.3.3 Grade C         Alekseev 2020       3       111       1       104       6.0%       2.81 [0.30, 26.60]
1.3.3 Grade C         Alekseev 2020       3       111       1       104       6.0%       2.81 [0.30, 26.60]         3enčurik 2021       3       100       5       100       29.1%       0.60 [0.15, 2.44]         3onadio 2020       0       33       3       20.4%       0.14 [0.01, 2.66]
Alekseev 2020       3       111       1       104       6.0%       2.81 [0.30, 26.60]         Benčurik 2021       3       100       5       100       29.1%       0.60 [0.15, 2.44]         Bonadio 2020       0       33       33       20.4%       0.14 [0.01, 2.66]         Sona 2020       4       253       5       253       29.1%       0.80 [0.22, 2.94]
3enčurik 2021 3 100 5 100 29.1% 0.60 [0.15, 2.44]
3onadio 2020 0 33 3 33 20.4% 0.14 [0.01, 2.66] ◆ ○on 2020 4 253 5 253 29.1% 0.80 [0.22 2.94]
Ton 2020 4 253 5 253 291% 0.80 (0.22.2.94)
3krovina 2020 1 50 0 20 4.1% 1.24 (0.05, 29.12)
Nada 2019 4 48 3 101 11.3% 2.81 [0.65, 12.04]
Subtotal (95% CI) 595 611 100.0% 0.97 [0.51, 1.87]
Fotal events 15 17
-leterogeneity: Chi <sup>2</sup> = 5.10, df = 5 (P = 0.40); i <sup>2</sup> = 2%
Fest for overall effect: Z = 0.08 (P = 0.93)
Eavours (experimental) Eavours (experimental)
ravous (experimental) ravous (control)
GORE 5

# Result

The detailed process of literature retrieval and screening is shown in Figure 1. A total of 1,007 papers were retrieved. After reading the title and abstract, we excluded 531 studies because they did not meet our inclusion criteria. A total of 22 studies (16-37) met the inclusion criteria among the remaining 94 potential included studies. From 2013 to 2021, 22 studies involving 4,738 patients from 10 countries were published. The sample size of the study ranged from 38 to 657 people. Three RCTs, three prospective studies, and sixteen retrospective studies were conducted. We scored 22 studies from 5 to 9 on the NOS, with 19 (86.4%) rated as high quality. Table 1 shows the basic information included in the study.

The combined results of 22 studies revealed that the total anastomotic leakage rates of the ICG and non-ICG groups were 3.7 and 7.6%, respectively (RR = 0.46; 95% CI, 0.39–0.56; p < 0.001; Figure 2).

As in the summary analysis, a similar relationship was observed for grade A anastomotic leakages but not for grades B and C. Grade A anastomotic leakage rate was 2.4% in the ICG group and 7.9% in the non-ICG group (RR = 0.25; 95% CI, 0.14–0.44; p < 0.00001); grade B: 2.9 and 3.9%, respectively (RR = 0.70; 95% CI, 0.38–1.31; p = 0.27); and grade C: 2.5 and 2.8%, respectively (RR = 0.97; 95% CI, 0.51–1.97; p = 0.93; Figure 3).

The subgroup analysis of 22 studies from different regions revealed that the rate of an astomotic leakage in the ICG group was 3.2% in Asia compared with 11.4% in the non-ICG group (RR = 0.33; 95% CI, 0.23–0.48; p < 0.00001), 6.5 and 14.1% in Europe (RR = 0.38; 95% CI, 0.27–0.53; p < 0.00001), and 6.0 and 9.4% in North America (RR = 0.72; 95% CI, 0.40–1.29; p = 0.27; Figure 4).

# **Publication bias**

Funnel plots were used to assess potential publication bias in a meta-analysis of the relationship between ICG use and anastomotic leakages. The funnel plot is symmetrical, as shown in Figure 5, indicating that the risk of deviation published in this study is low.

	ICG Gro	oup	Non-ICG G	iroup		<b>Risk Ratio</b>	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
1.2.1 Asian							
Foo 2020	9	253	20	253	7.7%	0.45 [0.21, 0.97]	
Hasegawa 2020	4	141	87	403	17.3%	0.13 [0.05, 0.35]	
Ishii 2020	4	116	11	104	4.5%	0.33 [0.11, 0.99]	
Kim 2017	2	310	18	347	6.5%	0.12 [0.03, 0.53]	
Wada 2019	5	48	7	101	1.7%	1.50 [0.50, 4.49]	
Watanabe 2021	10	211	22	211	8.4%	0.45 [0.22, 0.94]	
Zhou 2019	1	12	0	30	0.1%	7.15 [0.31, 164.36]	
Subtotal (95% CI)		1091		1449	46.2%	0.33 [0.23, 0.48]	•
Total events	35		165				
Heterogeneity: Chi <sup>2</sup> =	17.56, df	= 6 (P =	= 0.007); l <sup>2</sup>	= 66%			
Test for overall effect:	Z = 5.89	(P < 0.0	00001)				
1.2.2 Europe							
Alekseev 2020	16	111	27	104	10.7%	0.56 (0.32, 0.97)	
Benčurik 2021	9	100	19	100	7.3%	0.47 [0.23, 1.00]	<b>_</b>
Bonadio 2020	2	33	7	33	2.7%	0.29 [0.06 1.27]	
Boni 2017	ñ	42	2	38	1.0%	0.18 (0.01 3.66)	· · · · · · · · · · · · · · · · · · ·
Brescia 2018	Ň	21	4	31	1 4 %	0 16 0 01 2 85	· · · · · · · · · · · · · · · · · · ·
De Nardi 2019	4	56	7	53	2.8%	0.54 [0.17, 1.74]	
Impellizzeri 2020	, n	37	2	36	1.0%	0.19/0.01 3.92	·
Otero Piñeiro 2021	2	80	23	204	5.0%	0.22 [0.05 0.92]	
Ris 2018	3	90	39	365	5.9%	0.31 [0.10 0.99]	
Skrovina 2020	5	50	9	20	4.9%	0.22 [0.08, 0.58]	
Woicik 2020	1	26	6	42	1.8%	0.27 [0.03, 2.11]	
Subtotal (95% CI)		646	Ŭ	1026	44.4%	0.38 [0.27, 0.53]	◆
Total events	42		145			,	
Heterogeneity: Chi <sup>2</sup> =	5.35. df =	10 (P :	= 0.87);  2 =	0%			
Test for overall effect:	Z = 5.68 (	(P < 0.0	0001)				
123 North America							
lofori 2013	1	16	4	22	1 206	0.34 (0.04. 2.70)	
Jafari 2021	16	170	16	160	0.0.1	0.04 [0.04, 2.73]	
Mitrohi 2019	10	20	2	20	1 0.5 %	0.35 [0.43, 1.84]	
Shapara 2010	0	50	4	22	0.0%	0.20 [0.01, 4.00]	·
Subtotal (95% CI)	0	282		23	0.0%	0.14 [0.01, 3.21]	•
Total avanta	17	202	22	244	3.470	0.72 [0.40, 1.23]	-
Hotorogonoity: Chiž -	717 202 df-	2 /P -	0.40\-12=0	106			
Test for overall effect:	Z= 1.11 (	P = 0.2	0.40), 1 – 0 ?7)	170			
Total (05% CI)		2040		2740	100.0%	0 30 10 34 0 401	•
Total (95% CI)		2019	222	2/19	100.0%	0.59 [0.51, 0.49]	•
Letereners the Ohio	94	- 24 /5	333	- 2004			
Heterogeneity: Chi* =	29.62, df	= 21 (F	$r = 0.10)(1^{-1})$	= 29%			0.01 0.1 1 10 100
Test for overall effect:	∠ = 8.15 (	(P < U.L		(D - 0 0	0) 17 00	4.04	ICG Group Non-ICG Group
lest for subaroub diff	erences:	Uni*=	5.01. at = 2	(P = 0.0)	8). I* = 6U	1.1%	

# Discussion

The largest meta-analysis on the impact of ICGFA on anastomotic leakage in patients with rectal cancer surgery included 22 articles and 4,738 patients. The results of a pooled analysis of these patients revealed that the use of ICGFA during surgery was associated with a lower incidence of anastomotic leakage after rectal cancer resection. The results of a subgroup analysis of these patients revealed that the use of ICGFA during surgery in Asia and Europe was associated with a lower incidence of anastomotic leakage after rectal cancer resection and the use of ICGFA during surgery was associated with a lower incidence of grade A anastomotic leakage after rectal cancer resection.

The negative impact of anastomotic leakage after rectal cancer surgery cannot be ignored. Anastomotic leakage will result in prolonged hospitalization, increased hospitalization costs, increased local recurrence rate, and shortened survival time (38). Many studies have determined that anastomotic leakage is an independent risk factor for low long-term survival rate of patients with rectal cancer (39, 40). The study shows that anastomotic leakage risk factors have been determined in many situations, such as age, male gender, smoking, diabetes, previous radiotherapy and chemotherapy, intraoperative complications, anastomotic tension,



and low perfusion. These risk factors are partly related to patients, tumors, and surgery. Some risk factors are objective and cannot be changed, whereas other risk factors can be changed. Anastomotic perfusion is one of the few variables that can be changed.

ICG is a biocompatible near-infrared contrast agent that can be excited by external light with a wavelength of 750–800 nm and emit near-infrared light with a longer wavelength, allowing tissues and organs to develop. Because Nagata first used ICG in colorectal surgery in 2006, this technology has demonstrated significant research value and promising application prospects in the auxiliary diagnosis and treatment of colorectal cancer (41, 42). It has been reported in the literature that ICG near-infrared imaging technology can improve the visualization of tumor lesions, improve the detection rate of lymph nodes, and reduce the incidence of anastomotic leakage in laparoscopic colorectal cancer surgery (42).

The ICG near-infrared imaging technique is used to evaluate the intestinal blood supply at the anastomotic site during colorectal cancer surgery. Before the proximal intestinal wall is disconnected, the operator can use clinical judgment to select the resection line under white light or visible light and mark the "pre-resection line" on the intestinal wall without damage. However, it should be noted that unipolar or bipolar electrical equipment should be used to burn the mark to avoid damaging the local blood supply of the intestinal wall and ultimately affecting the accuracy of the assessment. After the location of intestinal resection was determined, ICG was injected intravenously for the first time, and vascular perfusion was monitored using a near-infrared camera system. If the ICG vascular perfusion imaging is good within 60 s, the intestinal blood supply is likely to be adequate. ICG has a median development time of 35 (29-44) s and a duration of 3 min. Record the boundary between perfusion and non-perfusion tissues of the intestinal tube and compare it with the previously marked "pre-resection line" of the intestinal tube before cutting the intestinal wall along the ischemic line. If the blood perfusion at the "pre-resection line" of the intestinal tube is deemed insufficient, the "pre-resection line" at the proximal end of the intestinal tube should be moved to a position with adequate blood perfusion. ICG was injected intravenously again after intestinal anastomosis. The perfusion after anastomosis was evaluated using a fluorescence system, and the blood supply and appearance of the intestinal wall were observed to determine whether the surgical strategy should be changed and intestinal anastomosis performed again.

The use of ICGFA in assessing anastomotic perfusion has been concerned in recent years due to its relative ease of use, low cost, and satisfactory safety (17, 21). Recently published metaanalyses (11-13) showed that the risk of anastomotic leakage after rectal surgery in patients with ICGFA was significantly reduced, which was consistent with our results. However, due to the limited number of articles included, the majority of the studies are inconclusive. In comparison to these studies, the advantage of our meta-analysis lies in the inclusion of all relevant RCT, prospective, and retrospective studies, allowing us to analyze a larger sample size than previous meta-analyses and produce more convincing research results. Simultaneously, our research object is more specific and singular, which is patients with rectal cancer undergoing surgical treatment. In patients undergoing rectal cancer resection, the incidence of anastomotic leakage is higher than in patients undergoing colon cancer surgery. Therefore, this group is most likely to benefit from this intervention.

According to a summary analysis of all patients, the use of ICGFA during surgery is associated with a reduction of anastomotic leakage after rectal cancer resection (RR = 0.25; 95% CI, 0.14-0.44; p < 0.00001). We found that using ICGFA during surgery was associated with a reduction in the incidence of anastomotic leakage after rectal cancer resection in Asia and Europe (RR = 0.33; 95% CI, 0.23–0.48; p < 0.00001 and RR = 0.38; 95% CI, 0.27-0.53; p < 0.00001) but not in North America (RR = 0.72; 95% CI, 0.40–1.29; p = 0.27). We believe that this is due to fewer studies and a smaller sample size, which causes heterogeneity in the analysis of results. The use of ICGFA during surgery is associated with a reduction in the incidence of grade A anastomotic leakage after rectal cancer resection (RR = 0.25; 95% CI, 0.14–0.44; p <0.00001), but there is no difference in the incidence of grades B and C anastomotic leakages (RR = 0.70; 95% CI, 0.38-1.31; p = 0.27and RR = 0.97; 95% CI, 0.51–1.97; p = 0.93). Therefore, we can conclude that ICGFA cannot reduce the occurrence of type B and C anastomotic leakages after rectal cancer resection. Because both the ICGFA intervention and control groups had a low incidence of types B and C anastomotic leakage, ICGFA could not reduce the incidence of types B and C anastomotic leakage after rectal cancer resection.

At the same time, we recognize that this study has some limitations. First, the diagnosis of anastomotic leakage varied across the studies. Some studies were diagnosed solely through radiology, whereas others were diagnosed through physical examination and endoscopy as well. Second, the dose of ICG administered and timing of the included studies were inconsistent. Third, restricted by the articles included, this study cannot be analyzed according to the level of rectal cancer. Finally, the number of RCTs in the study is insufficient, which may increase the risk of deviation. These limitations may result in heterogeneity in the analysis of research findings.

# Conclusion

In conclusion, the results of this systematic review and metaanalysis show that using ICGFA during rectal cancer surgery is associated with a significant reduction in AL. However, given the limitations mentioned above, more multicenter RCT studies with a large sample size are required in the future to demonstrate our research findings.

# Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://pubmed.ncbi.nlm. nih.gov/.

# Author contributions

SX: analysis, interpretation of data, and drafting the article or revising it critically for important intellectual content. WW: conception and design and final approval of the version to be published. LL, LM, LY, and YL: acquisition of

# References

1. Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. *Lancet.* (2019) 394:1467–80. doi: 10.1016/S0140-6736(19)32319-0

2. McDermott FD, Heeney A, Kelly ME, Steele RJ, Carlson GL, Winter DC. Systematic review of preoperative, intraoperative and postoperative risk factors for colorectal anastomotic leaks. *Br J Surg.* (2015) 102:462–79. doi: 10.1002/bjs.9697

3. Ptok H, Marusch F, Meyer F, Schubert D, Gastinger I, Lippert H, et al. Impact of anastomotic leakage on oncological outcome after rectal cancer resection. *Br J Surg.* (2007) 94:1548–54. doi: 10.1002/bjs.5707

4. Merkel S, Wang WY, Schmidt O, Dworak O, Wittekind C, Hohenberger W, et al. Locoregional recurrence in patients with anastomotic leakage after anterior resection for rectal carcinoma. *Colorectal Dis.* (2001) 3:154–60. doi: 10.1046/j.1463-1318.2001.00232.x

5. Ha GW, Kim JH, Lee MR. Oncologic impact of anastomotic leakage following colorectal cancer surgery: a systematic review and meta-analysis. *Ann Surg Oncol.* (2017) 24:3289–99. doi: 10.1245/s10434-017-5881-8

6. Chadi SA, Fingerhut A, Berho M, DeMeester SR, Fleshman JW, Hyman NH, et al. Emerging trends in the etiology, prevention, and treatment of gastrointestinal anastomotic leakage. *J Gastrointest Surg.* (2016) 20:2035–51. doi: 10.1007/s11605-016-3255-3

7. Vignali A, Gianotti L, Braga M, Radaelli G, Malvezzi L, Di Carlo V. Altered microperfusion at the rectal stump is predictive for rectal anastomotic leak. *Dis Colon Rectum.* (2000) 43:76–82. doi: 10.1007/BF02237248

8. Kusano M, Tajima Y, Yamazaki K, Kato M, Watanabe M, Miwa M. Sentinel node mapping guided by indocyanine green fluorescence imaging: a new method for sentinel node navigation surgery in gastrointestinal cancer. *Dig Surg.* (2008) 25:103–8. doi: 10.1159/000121905

9. Lin J, Lin LS, Chen DR, Lin KJ, Wang YF, Chang YJ. Indocyanine green fluorescence method for sentinel lymph node biopsy in breast cancer. *Asian J Surg.* (2020) 43:1149–53. doi: 10.1016/j.asjsur.2020.02.003

10. Lu J, Huang CM. Exploration and development of indocyanine green fluorescence applied in laparoscopic splenic hilum lymph node dissection for gastric cancer. *Zhonghua Zhong Liu Za Zhi.* (2019) 41:900–3. doi: 10.3760/cma.j.issn.0253-3766.2019.12.004

11. Pang HY, Chen XL, Song XH, Galiullin D, Zhao LY, Liu K, et al. Indocyanine green fluorescence angiography prevents anastomotic leakage in rectal cancer surgery: a systematic review and meta-analysis. *Langenbecks Arch Surg.* (2021) 406:261–71. doi: 10.1007/s00423-020-02077-6

12. Song M, Liu J, Xia D, Yao H, Tian G, Chen X, et al. Assessment of intraoperative use of indocyanine green fluorescence imaging on the incidence of anastomotic leakage after rectal cancer surgery: a PRISMA-compliant systematic review and meta-analysis. *Tech Coloproctol.* (2021) 25:49–58. doi: 10.1007/s10151-020-02335-1

13. Li Z, Zhou Y, Tian G, Liu Y, Jiang Y, Li X, et al. Meta-analysis on the efficacy of indocyanine green fluorescence angiography for reduction of anastomotic leakage

data. All authors contributed to the article and approved the submitted version.

# **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

after rectal cancer surgery. Am Surg. (2021) 87:1910-9. doi: 10.1177/0003134820 982848

14. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med.* (2009) 6:e1000100. doi: 10.1371/journal.pmed.1000100

15. Rahbari NN, Weitz J, Hohenberger W, Heald RJ, Moran B, Ulrich A, et al. Definition and grading of anastomotic leakage following anterior resection of the rectum: a proposal by the International Study Group of Rectal Cancer. *Surgery.* (2010) 147:339–51 doi: 10.1016/j.surg.2009.10.012

16. Jafari MD, Lee KH, Halabi WJ, Mills SD, Carmichael JC, Stamos MJ, et al. The use of indocyanine green fluorescence to assess anastomotic perfusion during robotic assisted laparoscopic rectal surgery. *Surg Endosc.* (2013) 27:3003–8. doi: 10.1007/s00464-013-2832-8

17. Kim JC, Lee JL, Park SH. Interpretative guidelines and possible indications for indocyanine green fluorescence imaging in robot-assisted sphincter-saving operations. *Dis Colon Rectum*. (2017) 60:376–84. doi: 10.1097/DCR.000000000000782

18. Boni L, Fingerhut A, Marzorati A, Rausei S, Dionigi G, Cassinotti E. Indocyanine green fluorescence angiography during laparoscopic low anterior resection: results of a case-matched study. *Surg Endosc.* (2017) 31:1836–40. doi: 10.1007/s00464-016-5181-6

19. Brescia A, Pezzatini M, Romeo G, Cinquepalmi M, Pindozzi F, Dall'Oglio A, et al. Indocyanine green fluorescence angiography: a new ERAS item. *Updates Surg.* (2018) 70:427–32. doi: 10.1007/s13304-018-0590-9

20. Mizrahi I, Abu-Gazala M, Rickles AS, Fernandez LM, Petrucci A, Wolf J, et al. Indocyanine green fluorescence angiography during low anterior resection for low rectal cancer: results of a comparative cohort study. *Tech Coloproctol.* (2018) 22:535–40. doi: 10.1007/s10151-018-1832-z

21. Ris F, Liot E, Buchs NC, Kraus R, Ismael G, Belfontali V, et al. Multicentre phase II trial of near-infrared imaging in elective colorectal surgery. *Br J Surg.* (2018) 105:1359–67. doi: 10.1002/bjs.10844

22. Shapera E, Hsiung RW. Assessment of anastomotic perfusion in left-sided robotic assisted colorectal resection by indocyanine green fluorescence angiography. *Minim Invasive Surg.* (2019) 2019:3267217. doi: 10.1155/2019/3267217

23. Watanabe J, Ishibe A, Suwa Y, Suwa H, Ota M, Kunisaki C, et al. Indocyanine green fluorescence imaging to reduce the risk of anastomotic leakage in laparoscopic low anterior resection for rectal cancer: a propensity score-matched cohort study. *Surg Endosc.* (2020) 34:202–8. doi: 10.1007/s00464-019-06751-9

24. De Nardi P, Elmore U, Maggi G, Maggiore R, Boni L, Cassinotti E, et al. Intraoperative angiography with indocyanine green to assess anastomosis perfusion in patients undergoing laparoscopic colorectal resection: results of a multicenter randomized controlled trial. *Surg Endosc.* (2020) 34:53–60. doi: 10.1007/s00464-019-06730-0

25. Wada T, Kawada K, Hoshino N, Inamoto S, Yoshitomi M, Hida K, et al. The effects of intraoperative ICG fluorescence angiography in laparoscopic low

anterior resection: a propensity score-matched study. Int J Clin Oncol. (2019) 24:394–402. doi: 10.1007/s10147-018-1365-5

26. Zhou SC, Tian YT, Wang XW, Zhao CD, Ma S, Jiang J, et al. Application of indocyanine green-enhanced near-infrared fluorescence-guided imaging in laparoscopic lateral pelvic lymph node dissection for middle-low rectal cancer. *World J Gastroenterol.* (2019) 25:4502–11. doi: 10.3748/wjg.v25.i31.4502

27. Alekseev M, Rybakov E, Shelygin Y, Chernyshov S, Zarodnyuk I. A study investigating the perfusion of colorectal anastomoses using fluorescence angiography: results of the FLAG randomized trial. *Colorectal Dis.* (2020) 22:1147–53. doi:10.1111/codi.15037

28. Bonadio L, Iacuzzo C, Cosola D, Cipolat Mis T, Giudici F, Casagranda B, et al. Indocyanine green-enhanced fluorangiography (ICGf) in laparoscopic extraperitoneal rectal cancer resection. *Updates Surg.* (2020) 72:477–82. doi: 10.1007/s13304-020-00725-6

29. Foo CC, Ng KK, Tsang J, Wei R, Chow F, Chan TY, et al. Colonic perfusion assessment with indocyanine-green fluorescence imaging in anterior resections: a propensity score-matched analysis. *Tech Coloproctol.* (2020) 24:935–42. doi: 10.1007/s10151-020-02232-7

30. Hasegawa H, Tsukada Y, Wakabayashi M, Nomura S, Sasaki T, Nishizawa Y, et al. Impact of intraoperative indocyanine green fluorescence angiography on anastomotic leakage after laparoscopic sphincter-sparing surgery for malignant rectal tumors. *Int J Colorectal Dis.* (2020) 35:471–80. doi: 10.1007/s00384-019-03490-0

31. Impellizzeri HG, Pulvirenti A, Inama M, Bacchion M, Marrano E, Creciun M, et al. Near-infrared fluorescence angiography for colorectal surgery is associated with a reduction of anastomotic leak rate. *Updates Surg.* (2020) 72:991-8. doi: 10.1007/s13304-020-00758-x

32. Skrovina M, Bencurik V, Martinek L, Machackova M, Bartos J, Andel P, et al. The significance of intraoperative fluorescence angiography in miniinvasive low rectal resections. *Wideochir Inne Tech Maloinwazyjne.* (2020) 15:43–8. doi: 10.5114/wiitm.2019.84851

33. Wojcik M, Doussot A, Manfredelli S, Duclos C, Paquette B, Turco C, et al. Intraoperative fluorescence angiography is reproducible and reduces the rate of anastomotic leak after colorectal resection for cancer: a prospective case-matched study. *Colorectal Dis.* (2020) 22:1263–70. doi: 10.1111/codi.15076 34. Ishii M, Hamabe A, Okita K, Nishidate T, Okuya K, Usui A, et al. Efficacy of indocyanine green fluorescence angiography in preventing anastomotic leakage after laparoscopic colorectal cancer surgery. *Int J Colorectal Dis.* (2020) 35:269–75. doi: 10.1007/s00384-019-03482-0

35. Benčurik V, Škrovina M, Martínek L, Bartoš J, Macháčková M, Dosoudil M, et al. Intraoperative fluorescence angiography and risk factors of anastomotic leakage in mini-invasive low rectal resections. *Surg Endosc.* (2021) 35:5015–23. doi: 10.1007/s00464-020-07982-x

36. Jafari MD, Pigazzi A, McLemore EC, Mutch MG, Haas E, Rasheid SH, et al. Perfusion assessment in left-sided/low anterior resection (PILLAR III): a randomized, controlled, parallel, multicenter study assessing perfusion outcomes with PINPOINT near-infrared fluorescence imaging in low anterior resection. *Dis Colon Rectum*. (2021) 64:995-1002. doi: 10.1097/DCR.0000000002007

37. Otero-Piñeiro AM, de Lacy FB, Van Laarhoven JJ, Martín-Perez B, Valverde S, Bravo R, et al. The impact of fluorescence angiography on anastomotic leak rate following transanal total mesorectal excision for rectal cancer: a comparative study. *Surg Endosc.* (2021) 35:754–62. doi: 10.1007/s00464-020-07442-6

38. Kryzauskas M, Bausys A, Degutyte AE, Abeciunas V, Poskus E, Bausys R, et al. Risk factors for anastomotic leakage and its impact on long-term survival in left-sided colorectal cancer surgery. *World J Surg Oncol.* (2020) 18:205. doi: 10.1186/s12957-020-01968-8

39. Lu ZR, Rajendran N, Lynch AC, Heriot AG, Warrier SK. Anastomotic leaks after restorative resections for rectal cancer compromise cancer outcomes and survival. *Dis Colon Rectum.* (2016) 59:236–44. doi: 10.1097/DCR.00000000000554

40. Wang S, Liu J, Wang S, Zhao H, Ge S, Wang W. Adverse effects of anastomotic leakage on local recurrence and survival after curative anterior resection for rectal cancer: a systematic review and meta-analysis. *World J Surg.* (2017) 41:277–84. doi: 10.1007/s00268-016-3761-1

41. Nagata K, Endo S, Hidaka E, Tanaka J, Kudo SE, Shiokawa A. Laparoscopic sentinel node mapping for colorectal cancer using infrared ray laparoscopy. *Anticancer Res.* (2006) 26:2307–11.

42. Keller DS, Ishizawa T, Cohen R, Chand M. Indocyanine green fluorescence imaging in colorectal surgery: overview, applications, and future directions. *Lancet Gastroenterol Hepatol.* (2017) 2:757–66. doi: 10.1016/S2468-1253(17)30216-9